Future research efforts should allow ESR1 mutational status to be used as an integral biomarker in trials on ER-positive breast cancer and to be tested prospectively as a stratification factor, as an enrichment strategy and as a therapeutic target in the development of new strategies to overcome endocrine resistance in breast cancer. Here, ESR1 is linked to breast cancer.